170 related articles for article (PubMed ID: 30310784)
21. An unusual case of Waldenstrom's macroglobulinemia presented with nasopharyngeal involvement.
Sathyanarayanan V; Das U; Shankaranand B; Gupta S; Anvekar NJ; Lakshmaiah K
Ecancermedicalscience; 2013; 7():362. PubMed ID: 24171046
[TBL] [Abstract][Full Text] [Related]
22. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders.
Pangalis GA; Kyrtsonis MC; Kontopidou FN; Vassilakopoulos TP; Siakantaris MP; Dimopoulou MN; Kittas C; Angelopoulou MK
Semin Oncol; 2003 Apr; 30(2):201-5. PubMed ID: 12720136
[TBL] [Abstract][Full Text] [Related]
23. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T
PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040
[TBL] [Abstract][Full Text] [Related]
24. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
[TBL] [Abstract][Full Text] [Related]
25. Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom's Macroglobulinemia.
Kazmierski D; Palomba ML; Barsigian C
Case Rep Hematol; 2017; 2017():5183646. PubMed ID: 28286680
[TBL] [Abstract][Full Text] [Related]
26. Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.
Kristinsson SY; Eloranta S; Dickman PW; Andersson TM; Turesson I; Landgren O; Björkholm M
Am J Hematol; 2013 Jan; 88(1):60-5. PubMed ID: 23165980
[TBL] [Abstract][Full Text] [Related]
27. Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept.
Lin P; Medeiros LJ
Adv Anat Pathol; 2005 Sep; 12(5):246-55. PubMed ID: 16210920
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma.
Motomura Y; Umezawa Y; Arimatsu T; Okada K; Miura O; Kumagai T
Clin Case Rep; 2022 Feb; 10(2):e05372. PubMed ID: 35154721
[TBL] [Abstract][Full Text] [Related]
29. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.
Paiva B; Montes MC; García-Sanz R; Ocio EM; Alonso J; de Las Heras N; Escalante F; Cuello R; de Coca AG; Galende J; Hernández J; Sierra M; Martin A; Pardal E; Bárez A; Alonso J; Suarez L; González-López TJ; Perez JJ; Orfao A; Vidríales MB; San Miguel JF
Leukemia; 2014 Jan; 28(1):166-73. PubMed ID: 23604227
[TBL] [Abstract][Full Text] [Related]
30. Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients.
Lin P; Bueso-Ramos C; Wilson CS; Mansoor A; Medeiros LJ
Am J Surg Pathol; 2003 Aug; 27(8):1104-13. PubMed ID: 12883242
[TBL] [Abstract][Full Text] [Related]
31. Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders.
Pangalis GA; Kyrtsonis MC; Kontopidou FN; Siakantaris MP; Dimopoulou MN; Vassilakopoulos TP; Tzenou T; Kokoris S; Dimitriadou E; Kalpadakis C; Tsalimalma K; Tsaftaridis P; Panayiotidis P; Angelopoulou MK
Clin Lymphoma; 2005 Mar; 5(4):235-40. PubMed ID: 15794855
[TBL] [Abstract][Full Text] [Related]
32. An Extended Prognostic Index of the ISSWM Score Based on Thyroid Complications in Waldenström Macroglobulinemia/Lymphoplasmacytoid Lymphoma.
Hu X; Wang H; Yuan D; Qu H; Li Y; Wang N; Wang X; Liu X; Xu H; Zhang Y; Wang X
Front Oncol; 2022; 12():870258. PubMed ID: 35646661
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.
Cao X; Medeiros LJ; Xia Y; Wang X; Thomas SK; Loghavi S; Li X; Shah JJ; Gustafson SA; Weber DM; Miranda RN; Xu-Monette ZY; Orlowski RZ; Young KH
Leuk Lymphoma; 2016 May; 57(5):1104-13. PubMed ID: 26421453
[TBL] [Abstract][Full Text] [Related]
34. Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis.
Rossi D
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):113-8. PubMed ID: 25696843
[TBL] [Abstract][Full Text] [Related]
35. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
[TBL] [Abstract][Full Text] [Related]
36. Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
Naderi N; Yang DT
Arch Pathol Lab Med; 2013 Apr; 137(4):580-5. PubMed ID: 23544948
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?
Berger F; Traverse-Glehen A; Felman P; Callet-Bauchu E; Baseggio L; Gazzo S; Thieblemont C; Ffrench M; Magaud JP; Salles G; Coiffer B
Clin Lymphoma; 2005 Mar; 5(4):220-4. PubMed ID: 15794852
[TBL] [Abstract][Full Text] [Related]
38. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation.
Walsh SH; Laurell A; Sundström G; Roos G; Sundström C; Rosenquist R
Leuk Res; 2005 Jul; 29(7):729-34. PubMed ID: 15927667
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
Wagner-Johnston ND; Schuster SJ; deVos S; Salles G; Jurczak WJ; Flowers CR; Viardot A; Flinn IW; Martin P; Xing G; Rajakumaraswamy N; Gopal AK
Leuk Lymphoma; 2021 May; 62(5):1077-1087. PubMed ID: 33300385
[TBL] [Abstract][Full Text] [Related]
40. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
